Ads
related to: advanced renal cell carcinoma- How This Treatment Works
Learn More About How This
FDA-Approved Treatment Works.
- FAQs
Find FAQs For This Treatment
Option On The Official Patient Site
- Dosing Information
Get Dosing And Treatment
Schedule Information.
- Patient Resources
Find Patient Resources
On The Official Site.
- How This Treatment Works
Search results
GRIT and Quangang announce IL-2 T-cell therapy partnership
Pharmaceutical Technology via Yahoo Finance· 10 hours agoQuanqi (125SER) is a marketed human Interleukin-2 used in treating solid tumours including renal ...
Moderna & Merck Announce 3-Year Data For mRNA-4157 (V940) in Combination With KEYTRUDA(R)...
Digital Journal· 9 hours agoAt a median planned follow-up of the Phase 2b study at 34.9 months, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% and the risk of distant metastasis ...
Exelixis (EXEL) Down 6.6% Since Last Earnings Report: Can It Rebound?
Zacks via Yahoo Finance· 4 days agoCabometyx (cabozantinib) generated revenues of $376.4 million, which missed the Zacks Consensus...
GRIT and Quangang Forge Strategic Partnership to Accelerate Localization of Interleukin-2
The Pilot News· 3 days agoCo., Ltd. (GRIT) and Shandong Quangang Pharmaceutical Co., Ltd. (Quangang) announced the establishment of a formal strategic partnership to leverage both parties' R&D capabilities in innovative ...
Moderna (MRNA) Stock Outperformed Industry YTD: Here's Why
Zacks via Yahoo Finance· 6 days agoModerna/Merck also started two separate mid-stage studies in renal cell carcinoma and...
Small Business - Salisbury Post | Salisbury Post
The Salisbury Post· 22 hours agoThe rolling BLA submission, initiated in December 20233 with timelines pre-agreed with the FDA, was based on Telix’s successful global Phase III ZIRCON4 study in ccRCC. The...
Small Business - The Brewton Standard | The Brewton Standard
The Brewton Standard· 2 days agoThe data will be presented today, on June 1, 2024, in a poster session at the 2024 American Society of Clinical Oncology (ASCO) Annual ...
EMA Panel Nods to Seven New Cancer Drugs
Medscape· 4 days agoThe drugs include an anti–PD-L1 monoclonal antibody, a biosimilar, and five generics, with indications covering a wide spectrum of cancers.
New Study Finds Increased Disparities in Cancer Su | Newswise
Newswise· 3 days agoA new study led by researchers at the American Cancer Society (ACS) shows increased disparities in...
Exelixis (NASDAQ:EXEL) Shares Gap Up on Insider Buying Activity
ETF DAILY NEWS· 2 days agoExelixis, Inc. (NASDAQ:EXEL – Get Free Report) shares gapped up before the market opened on Friday after an insider bought additional shares in the company. Exelixis shares last traded at $21.52 ...
Ads
related to: advanced renal cell carcinoma
